<Immunogenicity>Neutralizing antibody conversion rate against SARS-CoV-2 at 28 days after the second dose of study product in each group<Safety>The incidence and causal relationship to the study products of all adverse events; adverse events resulting in death; serious adverse events other than death; important adverse events; and severe (Grade 3 or higher) adverse events occurring after the first dose of study product to the examination 28 days after the second dose in each groupThe incidence and causal relationship to the study products of adverse events resulting in death; serious adverse events other than death; and severe (Grade 3 or higher) adverse events occurring after the examination 28 days after the second dose to the completion of follow-up in each groupThe incidence; severity; number of days to onset; duration; incidence by the first/second dose; and causal relationship to the study products of solicited local adverse events in each groupThe incidence; severity; number of days to onset; duration; incidence by the first/second dose; and causal relationship to the study products of solicited systemic adverse events in each groupThe incidence; severity; number of days to onset; duration; incidence by the first/second dose; and causal relationship to the study products of unsolicited adverse events in each groupThe highest body temperature between each administration of the study product and 6 days post-injection in each group

<Immunogenicity>Neutralizing antibody conversion rate against SARS-CoV-2 at 28 days after the second dose of study product in each group<Safety>The incidence and causal relationship to the study products of all adverse events; adverse events resulting in death; serious adverse events other than death; important adverse events; and severe (Grade 3 or higher) adverse events occurring after the first dose of study product to the examination 28 days after the second dose in each groupThe incidence and causal relationship to the study products of adverse events resulting in death; serious adverse events other than death; and severe (Grade 3 or higher) adverse events occurring after the examination 28 days after the second dose to the completion of follow-up in each groupThe incidence; severity; number of days to onset; duration; incidence by the first/second dose; and causal relationship to the study products of solicited local adverse events in each groupThe incidence; severity; number of days to onset; duration; incidence by the first/second dose; and causal relationship to the study products of solicited systemic adverse events in each groupThe incidence; severity; number of days to onset; duration; incidence by the first/second dose; and causal relationship to the study products of unsolicited adverse events in each groupThe highest body temperature between each administration of the study product and 6 days post-injection in each group